Biotech funding has improved this year but remains well below the post-pandemic boom. Still, picking winners in the sector requires deep knowledge and investor discipline.
China and India spend just 3% of GDP on healthcare, as against 16% in the US, but that figure is set to grow far faster than in developed markets, says Andy Acker of Janus Capital.